Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Oppenheimer analyst Matthew Biegler maintained a Buy rating on IDEAYA Biosciences (IDYAResearch Report) today and set a price target of $20.00. The company’s shares closed yesterday at $10.20.

According to TipRanks, Biegler is an analyst with an average return of -3.3% and a 31.11% success rate. Biegler covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Fate Therapeutics, and Blueprint Medicines.

In addition to Oppenheimer, IDEAYA Biosciences also received a Buy from Robert W. Baird’s Joel Beatty in a report issued today. However, yesterday, Stifel Nicolaus downgraded IDEAYA Biosciences (NASDAQ: IDYA) to a Hold.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $28.00 and a one-year low of $8.14. Currently, IDEAYA Biosciences has an average volume of 299.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Read More on IDYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More